Results 21 to 30 of about 20,678 (258)
Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors
World Journal of Diabetes, 2022 SGLT-2 inhibitors (SGLT-2Is) have significantly improved cardio-renal outcomes and are preferred agents in people with cardiovascular diseases, heart failure, and diabetic kidney disease. Similarly, GLP-1 receptor agonists (GLP-1RAs) have significantly improved atherosclerotic cardiovascular outcomes. To this end, DPP-4 inhibitors (DPP-4Is) are cardiac-
Singh, Awadhesh Kumar, Singh, Ritu
openaire +2 more sources
Physiology, pharmacology and prospects for dipeptidilpeptidase-4 inhibitors use
Фармация и фармакология (Пятигорск), 2023 Modern requirements for the treatment of type 2 diabetes mellitus (DM2) include not only achieving a glycemic control, but also reducing the risk of developing cardiovascular complications.
D. V. Kurkin +9 more
doaj +1 more source
3D-QSAR-based pharmacophore determination and design of novel DPP-4 inhibitors [PDF]
Scripta Medica, 2022 Background/Aim: Therapy of diabetes mellitus type 2 includes drugs that act as inhibitors of dipeptidyl peptidase 4 (DPP-4) enzyme. Several DPP-4 inhibitors are marketed today and although they have favourable safety profile and tolerability, they show ...
Rogić Sanja, Gagić Žarko
doaj +1 more source
DPP-4 Inhibition and the Path to Clinical Proof
Frontiers in Endocrinology, 2019 In the 1990s it was discovered that the enzyme dipeptidyl peptidase-4 (DPP-4) inactivates the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).
Bo Ahrén
doaj +1 more source
Journal of Research in Medical Sciences, 2022 Background: COVID-19 is responsible for the latest pandemic. Dipeptidyl peptidase-4 (DPP-4) is one of the cellular receptors of interest for coronavirus. The aim of this study was to assess the roles of DPP-4 inhibitors in prognosis of COVID-19 infection
Mohammad Sadidi +5 more
doaj +1 more source
Scientific Reports, 2018 The use of dipeptidyl peptidase-4 (DPP-4) inhibitors may be associated with pancreatic cancer and acute pancreatitis. Recent meta-analyses have reported conflicting findings.
Lana C. Pinto +4 more
doaj +1 more source
Frontiers in Pharmacology, 2017 Diabetes mellitus has been demonstrated to be closely associated with osteoporosis. Accordingly, hypoglycemic therapy is considered effective in treating metabolic bone disease.
Yinqiu Yang +4 more
doaj +1 more source
Journal of Enzyme Inhibition and Medicinal Chemistry, 2018 Dipeptidyl peptidase 4 (DPP-4) inhibitors are used for the treatment of type-2 diabetes mellitus. Various synthetic inhibitors have been developed to date, and plants containing natural DPP-4 inhibitors have also been identified.
Eisuke Kato +2 more
doaj +1 more source
Editorial – COVID-19 pandemic: is it time to learn about DPP-4/CD26? [PDF]
CellR4, 2020 The rapid spread of SARS-CoV-2, a novel coronavirus that emerged in late 2019, and the resulting COVID-19 pandemic, has been labeled as a public health emergency of international concern by the World Health Organization.
M. Maia Pinheiro +2 more
doaj +1 more source
Frontiers in Pharmacology, 2017 Background and Objectives: Limited research focuses on the risk of ischemic cerebrovascular disease associated with use of dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) in patients with type 2 diabetes mellitus in Taiwan.
Shih-Wei Lai +7 more
doaj +1 more source